Factors Related Analysis to Premature Withdrawal of Antiviral Therapy in Chronic Hepatitis C Patients Treated With Pegylated Interferon α-2b Plus Ribavirin
碩士 === 經國管理暨健康學院 === 健康產業管理研究所 === 102 === Aims:The major recent advance in CHC treatment has been the invention of combination therapy with pegylated IFN plus ribavirin. Despite the efficacy, it is sometimes accompanied by side effects that may lead to compromised medical adherence and early termin...
Main Authors: | Pen-Yuan Liu, 劉本雲 |
---|---|
Other Authors: | Ting-Chung Huang |
Format: | Others |
Language: | zh-TW |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/03463707487538307825 |
Similar Items
-
Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
by: T Kanda, et al.
Published: (2011-03-01) -
Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
by: Konstantinos D. Pantazis, et al.
Published: (2008-01-01) -
Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin
by: Fernando José de Novelli, et al.
Published: (2014-06-01) -
Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin
by: Chia-Min Wu, et al.
Published: (2021-03-01) -
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)